SHANGHAI, January 25, 2016 /PRNewswire/ -- CARsgen Therapeutics, a private and venture backed company focused on the development of CAR-T-based autologous immunotherapy to treat solid tumors, today announced the completion of a $30 million Series B private financing. KTB Ventures and Jolly Innovation Ventures led the round, which included participation from Kaitai Capital and JIC GenesisFountain Healthcare Ventures. Chi Hoon Hyun of KTB Ventures will join the board of directors in conjunction with the financing.